ESMO Clinical Practice Guideline on anal cancer: diagnosis, treatment and follow-up
The European guideline for anal cancer, covering staging, chemoradiotherapy for localised disease, salvage surgery, and chemotherapy and immunotherapy for cancer that has spread.
Overview
Evidence-graded guideline from the European Society for Medical Oncology on anal squamous cell carcinoma: diagnosis with MRI and PET-CT, HIV and HPV testing, radical chemoradiotherapy with fluorouracil (or capecitabine) and mitomycin using intensity-modulated radiotherapy, response assessment at 26 weeks, salvage abdominoperineal resection, and, for metastatic disease, carboplatin plus paclitaxel first line on the InterAACT result with anti-PD-1 antibodies after platinum.
It also addresses local excision for small perianal tumours, treatment in people living with HIV, and surveillance after treatment.
Most decisions on the localised and metastatic anal cancer pages, from the chemoradiotherapy schedule to when to operate and what to give for metastatic disease, follow this guideline or its American counterpart.
- Published before the POD1UM-303 result adding retifanlimab to first-line chemotherapy; check for updates.
- Evidence for many recommendations in this rare cancer comes from single trials or consensus.
Similar pages
not linked directly; found by shared links- TechnologyCirculating tumour HPV DNA (ctHPV-DNA)
Shares Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma.
- CancerAnal high-grade squamous intraepithelial lesions (precursor)
Shares Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma.
- TermHPV-positive (p16) head and neck cancer
Shares Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma.
- CancerAnal cancer (squamous cell carcinoma)
Shares Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma.